top of page

One-third of psoriasis patients have metabolic syndrome

Photo by James Heilman, MD via Wikimedia Commons

The global prevalence of metabolic syndrome (MetS) among patients with psoriasis is 32%, researchers report online in the Journal of the European Academy of Dermatology and Venereology.

These findings come from a systematic review and meta-analysis of records from five databases from their inception through Sept. 2021.

MetS is characterized by patients having at least three of five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). It is associated with the development of cardiovascular disease and type 2 diabetes.

While it has been known that psoriasis patients are at an increased risk of MetS, there has not previously been a systematic review to determine its global prevalence, the study’s authors note.

Overall, the investigators found a global prevalence of MetS in patients with psoriasis of 32% (95% confidence interval [CI], 0.26–0.38).

The prevalence was higher in adults (32% (95% CI, 0.29–0.36)) than in children and adolescents (9% (95% CI, 0.00–0.18)).

Broken down by region, Latin America had the highest prevalence at 47% (95% CI, 0.43–0.51). In contrast, the lowest prevalence was in North America, at 26% (95% CI, 0.16–0.37).

Prevalence was also higher in patients with psoriasis vulgaris (29%; 95% CI, 0.23–0.35) or severe psoriasis (37%; 95% CI, 0.27–0.46) compared to other forms of psoriasis.

“These findings suggest that MetS should be appropriately recognized and managed in patients with psoriasis. More population-based prospective observational studies are required to elucidate the mechanisms underlying the coexistence of MetS in patients with psoriasis,” the authors write.

13 views0 comments

Recent Posts

See All
bottom of page